亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

磺胺嘧啶銀,燒傷寧,磺胺嘧啶銀鹽,廠家直銷

 
 
單價 面議對比
詢價 暫無
發(fā)貨 湖北武漢市付款后3天內(nèi)
庫存 1000公斤起訂1公斤
品牌 武漢國邦達(dá)醫(yī)藥
型號 22199-08-2
規(guī)格 醫(yī)藥級
過期 長期有效
更新 2014-04-01 00:41
 

武漢國邦達(dá)醫(yī)藥化工有限公司

企業(yè)會員第14年
資料未認(rèn)證
保證金未繳納
  • 湖北-武漢市
  • 上次登錄 2014-04-01
  • 郭振華 (先生)   經(jīng)理
詳細(xì)說明

磺胺嘧啶銀

中文別名:燒傷寧; N-2-嘧啶基-4-氨基苯磺酰胺銀鹽; 酰胺銀鹽; 磺胺嘧啶銀鹽; 磺胺嘧啶銀(I) 

英文名稱:Silver Sulfadiazine 

英文別名:Sulfadiazine Silver salt; 4-Amino-N-2-pyrimidinylbenzenesulfonamide monosilver salt; SILVER(I) SULFADIAZINE; silver (4-aminophenyl)sulfonyl-pyrimidin-2-yl-azanide; SILVER SULPHADIAZINE; SULPHADIAZINE-AG; SULFADIAZINE SILVER; 4-amino-n-(2-pyrimidinyl)benzenesulfonamidesilversalt; 4-amino-n-2-pyrimidinyl-benzenesulfonamidmonosilver(1+)salt; dermazine; flamazine; 4-amino-N-(pyrimidin-2-yl)benzenesulfonamide; silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt  

CAS:22199-08-2 

分子式:C10H10AgN4O2S 

分子量:358.1447 

物化性質(zhì):為白色或類白色結(jié)晶性粉末。遇光或遇熱易變質(zhì)。 

執(zhí)行標(biāo)準(zhǔn):CP/USP 

含 量:99% 

產(chǎn)品用途:用于治療燒燙傷創(chuàng)面感染,除控制感染外,還可促使創(chuàng)面干燥、結(jié)痂和促進(jìn)愈合。涂藥后,遇光漸變成深棕色。 

包裝規(guī)格:25公斤/紙板桶。 

貯存條件:遮光,密閉,在陰涼處保存。

舉報收藏 0評論 0
更多>本企業(yè)其它產(chǎn)品
2-氰基吡啶,2-Cyanopyridine,廠家直銷
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |